Tumor Transcriptomics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Tumor Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Others), By Technology (Microarray, Real-Time Quantitative, Polymerase Chain Reaction (Q-PCR), Others), By Product (Consumables, Instrument, Software & Services), By Application (Diagnostics and Disease Profiling, Drug Discovery, Others), By End User (Biotechnology & Pharmaceutical Companies, Research & Academic Institutions, Others), and By Region, 2020-2030F

Market Overview

The Global Tumor Transcriptomics Market, valued at USD 6.02 Billion in 2024, is projected to experience a CAGR of 6.34% to reach USD 8.71 Billion by 2030. Tumor transcriptomics involves the comprehensive analysis of ribonucleic acid transcripts within cancer cells, providing essential insights into gene expression patterns, disease classification, and progression. This market’s expansion is primarily supported by the increasing global prevalence of various cancer types and continuous advancements in genomic sequencing technologies. According to the American Cancer Society, over 2 million new cancer cases were projected in the United States for 2024, significantly increasing the demand for precise diagnostic and prognostic tools in oncology. Further growth is driven by the rising adoption of personalized medicine strategies, which heavily rely on detailed molecular profiling.

A notable challenge impeding market expansion is the scarcity of professionals possessing specialized expertise in both molecular biology and the bioinformatics required for the complex analysis and interpretation of extensive transcriptomic datasets. This expertise gap can limit the effective integration and application of advanced tumor transcriptomics technologies in clinical and research settings.

Key Market Drivers

The escalating global incidence of cancer serves as a primary catalyst for the expansion of the tumor transcriptomics market. As cancer rates continue to rise across diverse populations, there is a sustained demand for sophisticated diagnostic and prognostic tools capable of unraveling complex molecular signatures of various tumor types. Tumor transcriptomics offers unparalleled insights into gene expression patterns and disease progression, crucial for effective clinical management and treatment stratification. According to the International Agency for Research on Cancer, in February 2024, "Global cancer burden growing, amidst mounting need for services" article, in 2022 there were an estimated 20 million new cancer cases worldwide, highlighting the extensive patient population requiring advanced molecular profiling. This pervasive disease burden necessitates continuous innovation in transcriptomic analysis to provide actionable information for clinicians.

Concurrently, advancements in sequencing technologies are fundamentally reshaping the landscape of tumor transcriptomics. Innovations in next-generation sequencing have significantly reduced costs and increased the speed and accuracy of transcriptomic profiling, making these complex analyses more accessible for research and clinical applications. According to the Wellcome Sanger Institute Blog, in February 2024, "Genomics gets faster, cheaper, and more accurate" article, by 2022 the institute could sequence a human genome for approximately $500, with newer platforms aiming for further reductions, facilitating broader studies and routine oncology application. This enhanced accessibility and throughput directly drives market growth. The ecosystem supporting such innovations reflects robust interest, evidenced by substantial financial commitments to the field. According to the Biotechnology Innovation Organization, as stated in the Cancer Research Horizons article "On the horizon: exploring investment trends" in June 2024, an estimated $8.6 billion globally went into oncology venture deals in 2023, underscoring significant investment in related genomic and precision medicine endeavors that underpin the tumor transcriptomics market's expansion.

Download Free Sample Report

Key Market Challenges

The scarcity of professionals possessing specialized expertise in both molecular biology and the bioinformatics required for complex analysis represents a significant impediment to the Global Tumor Transcriptomics Market's expansion. These specialists are critical for interpreting the vast and intricate transcriptomic datasets, which are fundamental for precise disease classification, understanding progression, and guiding therapeutic strategies. Without sufficient qualified personnel, the advanced genomic sequencing technologies, despite continuous advancements, cannot be fully leveraged.

This expertise gap directly creates bottlenecks in data analysis and interpretation, slowing the translation of research findings into clinical applications and limiting the effective integration of advanced tumor transcriptomics technologies. According to surveys cited in a 2025 report by the Global Organisation for Bioinformatics Learning, Education and Training (GOBLET), only about 25% of educational programs teach essential bioinformatics skills, indicating a substantial disparity between theoretical knowledge and practical application. This shortfall in specialized talent consequently hampers the widespread adoption and utilization of tumor transcriptomics, thereby restricting the market's overall growth potential.

Key Market Trends

The two most significant and distinct trends are the "Emergence of Spatial Tumor Transcriptomics for Tissue Analysis" and "Growing Adoption of RNA-Based Liquid Biopsy for Cancer Detection. " These trends represent advancements in understanding tumor architecture with unprecedented detail and a shift towards less invasive diagnostic methods, respectively, without overlapping with the previously stated market drivers of increasing cancer incidence and general sequencing technology advancements.

The emergence of spatial tumor transcriptomics for tissue analysis is significantly influencing the market by enabling researchers to precisely map gene expression within the architectural context of a tumor, providing insights into cellular interactions and disease microenvironments that bulk sequencing cannot. This technology is becoming crucial for understanding tumor heterogeneity and identifying novel biomarkers for targeted therapies. For example, Vizgen, a company at the forefront of this technology, announced the first global shipments of its MERSCOPE Ultra Platform in September 2024, delivering enhanced capabilities to leading research institutions worldwide to accelerate discoveries in spatial genomics. This advancement, which triples the imaging area of its predecessor to 3.0 cm² on a single slide and offers faster imaging speeds, underscores the growing demand for high-resolution spatial multiomic analysis systems to propel foundational and clinical research.

The growing adoption of RNA-based liquid biopsy for cancer detection is also a pivotal trend, as it offers a non-invasive alternative for comprehensive genomic profiling, especially when tissue biopsies are unfeasible or provide insufficient material. This method leverages circulating tumor RNA to provide real-time insights into tumor genetics and treatment response. For instance, in May 2024, Foundation Medicine launched its FoundationOne RNA test for clinical use in the US, a tissue-based RNA sequencing test that detects cancer-related fusions across 318 genes to aid in targeted therapeutic selection for various cancers. This commercial launch, following its availability for research purposes in September 2023, highlights the increasing clinical integration of RNA sequencing for comprehensive fusion detection in solid tumors like non-small cell lung cancer and pancreatic cancer, thereby expanding the utility of RNA-based diagnostics in oncology.

Segmental Insights

The breast cancer segment is experiencing rapid growth within the Global Tumor Transcriptomics Market, emerging as a leading driver of market expansion. This acceleration is predominantly fueled by the increasing demand for personalized medicine strategies to effectively manage the complex heterogeneity inherent in breast cancer, which traditional diagnostic methods often find challenging to fully characterize. Advanced transcriptomic profiling techniques, including RNA sequencing, provide comprehensive insights into gene expression patterns, facilitating precise molecular subtyping and the identification of novel therapeutic targets. This enhanced understanding of breast tumor biology is crucial for developing more accurate diagnostic tools and tailored treatment approaches, ultimately improving patient outcomes and stimulating widespread adoption in both clinical and research settings.

Regional Insights

North America leads the Global Tumor Transcriptomics Market, primarily driven by its robust research and development infrastructure and substantial investments from both public and private sectors in genomics and oncology. The region benefits from a significant presence of established biotechnology and pharmaceutical companies, alongside numerous leading research institutions. A high prevalence of cancer and other chronic diseases further fuels the demand for advanced diagnostic tools and personalized medicine approaches, which tumor transcriptomics uniquely provides. This mature ecosystem, supported by an advanced healthcare system and a framework for precision oncology, accelerates the adoption of innovative technologies, solidifying North America's dominant position.

Recent Developments

• In June 2025, Agenus Inc. and Noetik initiated a research collaboration focused on developing AI-enabled predictive biomarkers for Agenus' clinical-stage immunotherapy combination of botensilimab and balstilimab. This partnership utilizes Noetik's proprietary virtual cell foundation models and extensive multimodal tumor data, which integrates spatial transcriptomics, spatial proteomics, and H&E pathology. The collaboration aims to uncover novel insights into tumor immunology and identify actionable biomarkers to predict which patients across various cancer types are most likely to respond to the treatment, thereby accelerating precision immunotherapy.

• In February 2025, Illumina, Inc. announced a new spatial technology program aimed at advancing research by enabling unbiased whole-transcriptome profiling with cellular resolution and high sensitivity. This breakthrough innovation allows researchers to map complex tissues and understand cellular behavior on an unprecedented scale. The capabilities are expected to drive expansion of spatial research and unlock new applications, including those focused on understanding tumor microenvironments and prostate cancer. The Broad Institute is collaborating on a flagship project to utilize this new Illumina spatial technology.

• In February 2025, BGI-Research unveiled SpaTrack, an innovative computational tool for constructing spatiotemporal cell differentiation trajectories. This breakthrough research combines single-cell spatial transcriptomics with optimal transport theory, offering a comprehensive framework to elucidate how cells evolve, migrate, and specialize within dynamic biological contexts. Notably, SpaTrack has been applied successfully to map the expansion and metastatic routes in tumors, leveraging high-resolution data from BGI’s proprietary Stereo-seq technology, which captures both transcriptional profiles and spatial locations of individual cells in tissue samples.

• In January 2024, NanoString Technologies commercially launched its CosMx Human 6K Discovery Panel, an innovative product designed for high-plex spatial molecular imaging. This new panel significantly enhanced research capabilities by allowing scientists to measure over 6,000 RNA targets at single-cell resolution. The technology is particularly relevant to the Global Tumor Transcriptomics Market as it enables deeper exploration of cell states, functions, and intricate cell-to-cell interactions within a spatial context, providing crucial insights into tumor heterogeneity and immune microenvironments in various cancers, including pancreatic and colorectal cancer.

Key Market Players

• Thermo Fischer Scientific, Inc.
• Caris Life Sciences.
• Illumina, Inc.
• NanoString Technologies, Inc.
• 10x Genomics, Inc.
• Agilent Technologies, Inc.
• Bio-Rad Laboratories, Inc.
• F. Hoffmann-La Roche AG
• Standard BioTools Inc.
• Pacific Biosciences of California, Inc.

Report Scope:

In this report, the Global Tumor Transcriptomics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Tumor Transcriptomics Market, By Tumor Type:

o   Breast Cancer

o   Lung Cancer

o   Colorectal Cancer

o   Prostate Cancer

o   Melanoma

o   Others

• Tumor Transcriptomics Market, By Technology:

o   Microarray

o   Real-Time Quantitative

o   Polymerase Chain Reaction (Q-PCR)

o   Others

• Tumor Transcriptomics Market, By Product:

o   Consumables

o   Instrument

o   Software & Services

• Tumor Transcriptomics Market, By Application:

o   Diagnostics and Disease Profiling

o   Drug Discovery

o   Others

• Tumor Transcriptomics Market, By End User:

o   Biotechnology & Pharmaceutical Companies

o   Research & Academic Institutions

o   Others

• Tumor Transcriptomics Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Tumor Transcriptomics Market.

Available Customizations:

Global Tumor Transcriptomics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Tumor Transcriptomics Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]